News

Article

Advaxis, Ayala Pharmaceuticals Complete Merger

The merged company will operate under the name Ayala Pharmaceuticals and will target the development and commercialization of Ayala’s lead program, AL102, for the treatment of desmoid tumors.

On Jan. 19, 2023, Advaxis, Inc., a biotechnology company focused on the discovery, development, and commercialization of immunotherapies, completed a previously announced merger with Ayala Pharmaceuticals, Inc., a clinical-stage oncology company that develops and commercializes small molecule therapeutics for patients who have rare tumors and aggressive cancers.

The merged company will operate under the name Ayala Pharmaceuticals and will target the development and commercialization of Ayala’s lead program, AL102, for the treatment of desmoid tumors. AL102 has received Fast Track Designation from FDA and is currently in phase 3 of a trial for patients with desmoid tumors.

Source: Advaxis

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
 Benjamin McLeod and Sebastian Lykke Skafte Andersen go behind the headlines to examine the motivations behind recent M&A activity, tariff responses, and more.